Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PSAT1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PSAT1 Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for enzymatic assays and biophysical binding studies. |
View PSAT1 Products |
| Gene Delivery | PSAT1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View PSAT1 Products |
| Benchmark Ab | Anti-PSAT1 Recombinant Antibody High-affinity positive control for Western Blot, ELISA, and intracellular detection. |
View PSAT1 Products |
| Validator | PSAT1 siRNA Set Target-specific knockdown verification in cancer cell lines. |
View PSAT1 Products |
| Related Target A | PHGDH Upstream rate-limiting enzyme in the phosphorylated serine biosynthesis pathway. Crucial for combination screening. |
View PHGDH Products |
| Related Target B | PSPH Downstream phosphatase completing the serine synthesis pathway. Key target for metabolic network profiling. |
View PSPH Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against other transaminases (e.g., GOT1, GOT2) | High-purity recombinant panel proteins strictly verified by mass spectrometry and SDS-PAGE to ensure no cross-contamination. |
| Enzymatic activity assay reproducibility | Sequence-verified, low-endotoxin preparations with optimized buffer recommendations to preserve native-like folding. |
| Lack of Controls | Clinical Benchmark Antibodies and sequence-validated positive controls included in the portfolio. |
| False Positives in Small Molecule Screening | Validated siRNA sets included for target knockdown and specificity verification in phenotypic assays. |
Live PSAT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PSAT1 therapeutics is intensifying, with major players shifting focus from traditional metabolic profiling to targeted small molecule inhibitors and PROTACs. As first-generation serine synthesis pathway inhibitors reach preclinical and early clinical evaluation, the next wave of R&D is targeting PSAT1 to overcome chemotherapy resistance (such as 5-fluorouracil and oxaliplatin resistance in colorectal cancer) and to disrupt metabolic reprogramming in triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Colorectal Cancer, TNBC, NSCLC | Enzymatic Inhibition Assays (Need active, high-purity recombinant PSAT1) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Solid Tumors, Therapy-Resistant Cancers | Binary/Ternary Complex Validation (Need tag-specific PSAT1 proteins) |
| Combination Therapies (with PHGDH/PSPH inhibitors) | Oncology-focused Biopharma | Metastatic Cancers, Metabolic-driven Tumors | Pathway-wide Screening Panels (Need PHGDH, PSAT1, and PSPH target proteins) |